Prospective, Multicenter, Single-Arm Study of Aortic Arch Pathology Reconstruction (NCT07139912) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prospective, Multicenter, Single-Arm Study of Aortic Arch Pathology Reconstruction
China96 participantsStarted 2025-09
Plain-language summary
A prospective ,multiple center Study about the Safety and Efficacy of the Thoracic Aortic Multi-Branch Stent Graft System, developed and manufactured by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., in patients with aortic arch pathologies.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 to 80 years
✓. Diagnosed with aortic arch pathology requiring intervention, including:
✓. Deemed suitable for endovascular repair by the investigating physician
✓. Capable of understanding study objectives, providing written informed consent, and complying with follow-up requirements
✓. Anatomic suitability confirmed by CTA:
✓. High surgical risk per investigator assessment OR contraindicated for open surgery